Screener
ImmunityBio, Inc. IBRX Total Revenue
Total Revenue at other companies
Segments
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Revenue | ||
| Product revenue, net | $44,167 | $16,509 |
| Other revenues | 39 | 8 |
| Total revenue | 44,206 | 16,517 |
| Operating costs and expenses | ||
| Cost of sales | 238 | 58 |
| Research and development | 64,770 | 45,976 |
| Research and development – related parties | 3,219 | 2,258 |
ITEM 1. FINANCIAL STATEMENTS.
FAQ
- What is ImmunityBio, Inc.'s total revenue?
- ImmunityBio, Inc. (IBRX) reported total revenue of $44.21M in Q1 2026.
- How has ImmunityBio, Inc.'s total revenue changed year-over-year?
- ImmunityBio, Inc.'s total revenue increased by 167.6% year-over-year, from $16.52M to $44.21M.
- What is the long-term trend for ImmunityBio, Inc.'s total revenue?
- Over 4 years (2021 to 2025), ImmunityBio, Inc.'s total revenue has grown at a 231.9% compound annual growth rate (CAGR), from $934K to $113.29M.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about ImmunityBio, Inc.'s total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude